RAD June 2024 Abstracts and Posters
627 A checklist to aid in identifying patients with atopic dermatitis who are candidates for systemic therapy
Jonathan Silverberg, Matthias Augustin, Lawrence Eichenfield, Peter Lio, Emma Guttman-Yassky, Amber Reck Atwater, Evangeline Pierce, Maria Jose Rueda, Alvin Li, Yolanda Munoz Maldonado, Eric Simpson
628 Clinical measures of improvement in atopic dermatitis are correlated with reductions in relevant biomarkers in patients treated with lebrikizumab
Emma Guttman-Yassky, Angela Okragly, Zhe Sun, Brian J. Nickoloff, Chitra R Natalie, Gaia Gallo, Eric Wolf, Kilian Eyerich, Monica Aparici, Robert J. Benschop
629 A novel efficacy index for long-term therapy outcomes expressed by maintenance of EASI 75 and IGA 0,1 response in atopic dermatitis
Jonathan I. Silverberg, Alan Irvine, Peter Foley, James Del Rosso, Alexander Schacht, Martin Dossenbach, Marta Casillas, Erin Johansso, Gaia Gallo, Linda Stein Gold
630 Efficacy comparison of targeted systemic monotherapies including lebrikizumab for moderate-to-severe atopic dermatitis: a network meta-analysis
Jonathan I. Silverberg, Thomas Bieber, Amy Paller, Lisa A. Beck, Masahiro Kamata, Luis Puig, Marni Wiseman, Khaled Ezzedine, Peter Foley, Erin Johansson, Martin Dossenbach, Bülent Akmaz, Marta Casillas, Andrei Karlsson, Raj Chovatiya
633 Physician-assessed effectiveness and safety in adolescent and adult atopic dermatitis patients treated with dupilumab: real-world insights one year into the GLOBOSTAD multinational prospective observational study
Silvia M. Ferrucci, Piergiacomo Calzavara-Pinton, Iva Karlova, Hilde Lapeere, Gregor Holzer, Mona Al-Ahmad, Chia-Yu Chu, Jiangming Wu, Marius Ardeleanu, Kwinten Bosman
634 Patient-reported outcomes and safety in adolescent and adult atopic dermatitis patients treated with dupilumab: real-world insights one year into the GLOBOSTAD multinational prospective observational study
Dédée F. Murrell, Silvia M. Ferrucci, Caterina Foti, Bibiana Perez-Garcia, Hilde Lapeere, Piergiacomo Calzavara-Pinton, Anne-Claire Fougerousse, Jiangming Wu, Marius Ardeleanu, Kwinten Bosman
635 Dupilumab is efficacious in patients with prurigo nodularis regardless of baseline lesion severity: pooled results from two phase 3 trials (LIBERTY-PN PRIME and PRIME2)
Sonja Ständer, Laurent Misery, Gil Yosipovitch, Chang Ook Park, Lin-Feng Li, Amy Praestgaard, Joseph Zahn, Simmi Wiggins
637 ARQ-234: a high affinity CD200-Fc fusion protein for the treatment of atopic dermatitis
Joseph Sheridan, Jonathan Heal, David R. Berk, Patrick Burnett, David J Blackbourn, Philip Huxley, Rebecca Ashfield
638 Long-term safety and efficacy of roflumilast cream 0.15% in adults and children aged ≥6 years with mild to moderate atopic dermatitis: a 52-week, phase 3, open-label extension trial
Eric L. Simpson, Lawrence F. Eichenfield, Kim A. Papp, Seth Forman, Adelaide A. Hebert, Mercedes E.Gonzalez, Melinda Gooderham, H. Chih-ho Hong, Vimal H. Prajapati, Emma Guttman, Jonathan Silverberg, Melissa Seal, David Krupa, Patrick Burnett, Scott Synder, David H. Chu, Robert C. Higham, David R. Berk
639 Efficacy and safety of once-daily roflumilast cream 0.05% in pediatric patients 2 to 5 years of age with mild to moderate atopic dermatitis (INTEGUMENT-PED): a phase 3 randomized controlled trial
Lawrence Eichenfield, John Browning, Tracy Funk, Mercedes E. Gonzalez, Adelaide A. Hebert, Mark Lee, Vimal H. Prajapati, Rocco Serrao, Lisa Swanson, Robert Higham, David Berk